DMCBiotech, Author at DMC Biotechnologies

Made to Scale™: How DMC is solving the historical challenges of biomanufacturing

DMCBiotech — Mon, 15 May 2023 15:04:32 +0000

15 May 2023 – Biomanufacturing promises revolutionary, sustainable ways of producing material that the world uses every day – and governments are finally taking notice.

Support for biomanufacturing processes that can advance solutions in climate change and bolster national and economic security, like the executive order on advancing biotechnology and manufacturing is a welcome, much-needed pivot.

But with traditional processes of engineering biology coming at a cost and often turning into long, complicated endeavors, success has been too slow for a rapidly changing world that needs solutions now.

At DMC Biotechnologies, we’re taking the call to action for faster and effective biotechnology innovations seriously. DMC’s proprietary precision fermentation process is a holistic approach ushering in the next transformative wave of biotechnology with global implications.

By addressing the barriers that have challenged the industry for decades, the DMC process brings biomanufacturing into a new era, pioneering pathways needed for rapid commercialization, and in turn, sustainability that has an impact. DMC is the platform that is Made to Scale™.

Simplifying Biology for Scale

Microbes have evolved over millennia to respond to their environments as a means of survival. While that may be advantageous for survival in the wild, it has created the need for significant work in process development in the industrial environment.

It was a challenge that DMC Biotechnologies founders Dr. Matthew Lipscomb and Dr. Mike Lynch, chemical engineers who met in grad school, were all too familiar with. Having experienced first hand the labors, frustrations, and challenges of engineering biology, they were inspired to develop a better approach that addressed these challenges: Dynamic Metabolic Control™.

DMC’s technology uses a standardized, two-stage fermentation process that decouples the growth of the microbe from production of the desired product.

In traditional bioprocessing, the individual strains used for each production process require unique process development at each scale and are sensitive to even minor changes in the physical properties of the fermentation broth such as temperature, pH and dissolved oxygen (DO), which are unavoidable at commercial scale.

DMC’s precision fermentation technology limits the ability of the microbe to respond to the environment, simplifying biology and enabling predictable scale-up. This process creates the opportunity to reimagine how everyday products are made with applications that range from personal care to nutrition to the composite materials that we rely on every day.

A True Technology Platform

https://dmcbio.com/wp-content/uploads/2022/04/DMC-Technology.mp4

With DMC, the strain is more robust to the process environment, eliminating the need to develop a new process for each new strain, product, or scale. DMC’s platform enables bioprocesses that can tolerate a greater range of industrial process conditions, resulting in fewer lost batches and better economics than other approaches.

DMC further simplifies biomanufacturing by using a standardized set of equipment, operations, microbes and feedstocks. The frequent failure of small-scale screening studies to readily translate to larger-scale production processes has been a major factor inhibiting the commercialization of fermentation processes.

On the contrary, by combining standardization and process robustness DMC’s technology creates a pathway to predictable performance through a true platform technology that can produce bio-based chemicals for every product and at every scale.

Scaling to Commercial Success

DMC’s Made to Scale™ platform powers the efficient commercialization of bio-based chemicals, taking concepts to products quicker and more cost effectively than the traditional approach, which remains artisanal and exorbitantly costly.

By 2020, DMC Biotechnologies had produced four products with commercial performance metrics and demonstrated at scale (3000L scale fermentation). It has also brought its lead product, L-alanine, to 85,000L scale fermentation and has a full pipeline of products, with markets such as intermediate chemicals, nutrition, and personal and home care, among others. All of this was accomplished with an investment of less than $15 million – faster and more economical than any other technology in the field.

DMC Biotechnologies is now growing a pipeline of bio-based chemicals that it will deploy over the coming decade to meet the urgent need of faster and more cost effective success in biomanufacturing.

By addressing key barriers and streamlining product development with standardized, predictable and robust methods, DMC is creating a dramatic reduction of time-to-market and costs, transforming traditional product and chemical development that is better for consumers, and better for mitigating climate change.

Get in touch to learn more about how DMC fuses sustainable chemistry with business sense.

The post Made to Scale™: How DMC is solving the historical challenges of biomanufacturing appeared first on DMC Biotechnologies.

DMC invited by P&G Fabric and Home Care to pitch how precision fermentation can accelerate the journey to net zero by 2040

DMCBiotech — Wed, 22 Mar 2023 08:00:35 +0000

22 March 2023 – DMC Biotechnologies is delighted to have been given the opportunity to pitch in front of P&G Fabric and Home Care and more than 80 of their top suppliers at the company’s Sustainability, Equality & Inclusion Supplier Summit hosted at P&G’s Innovation Centre in Brussels.

Rusty Pittman, VP of Business Development, will pitch DMC’s precision fermentation technology and lead products at the event. DMC’s technology has been proven to address key barriers in the field and is the only approach that is Made to Scale™. This fits well with P&G’s approach to sustainable innovation because it is rooted in science, enables superior sustainability, and strengthens their supply chains to ensure business continuity in these increasingly volatile times.

The event is part of the “Cleaner, Better Together” programme that has been launched by P&G’s Fabric and Home Care division last year and aims to promote joint value creation by driving irresistible and sustainable superiority in partnership with top suppliers.

“P&G Fabric and Home Care are on a mission to decarbonize laundry while delighting consumers with irresistible superior product performance. We already have strong partnerships in place, but we don’t have all the answers yet, which is why we are calling on all moonshot thinkers – inventors, innovators, academics, start-ups, big and small companies – to help us innovate. The Supplier Summit in Brussels gives us, and our suppliers, a great opportunity to connect with potential new partners that could help us decarbonize the entire supply chain,” said Sundar Raman, Fabric and Home Care CEO.

DMC is thrilled to have been recognized as one of the select moonshot thinkers and we are looking forward to forming connections with P&G Fabric Care and their suppliers at this important summit.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Decarbonizing consumer goods requires scale. DMC has the only technology platform that is Made to Scale™. P&G is a household name in Home Care and provides access to massive channel scale for their products. We’re pleased to have the opportunity to showcase our products and technology as part of the P&G Supplier Summit and look forward to building end-to-end supply chains that deliver on scale, decarbonization, and exceeding customer expectations.”

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com
ks@sustainabilityconsult.com

About DMC
DMC is a US bio-based chemical company that makes products using microbial fermentation. DMC’s proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable.

DMC’s technology platform addresses the key barriers that have plagued the biotech industry for decades including standardization, robustness, and predictability across scale. Addressing these challenges translates to a dramatic reduction in the time to market and the investment needed to bring products to commercialization.

For more information, visit: www.dmcbio.com

The post DMC invited by P&G Fabric and Home Care to pitch how precision fermentation can accelerate the journey to net zero by 2040 appeared first on DMC Biotechnologies.

DMC Welcomes Inflation Reduction Act Inclusion of Advanced Manufacturing

DMCBiotech — Thu, 11 Aug 2022 16:15:53 +0000

11 August 2022 – The Inflation Reduction Act approved by the US Senate this week will lead to the direct investment of $369 billion in energy security and climate change programs over the next ten years. It is expected to go to the House of Representatives in the coming days.

The bill aims to reduce greenhouse gases by 40% below 2005 levels by 2030 and includes ambitious projects like putting a price on methane emissions, improving the energy efficiency of buildings and tackling issues like indoor air quality.

The bill is good news for advanced biofuels and clean energy technologies. Biochemicals companies may also be eligible to receive support under the Advanced Industrial Facilities Deployment Program which has $5.8 billion committed for advanced manufacturing and decarbonization.

The Advanced Industrial Facilities Deployment Program will invest in projects aimed at reducing emissions from energy-intensive industries, including the chemicals sector. It will support companies to purchase, install or implement advanced industrial technology, as well as to retrofit, upgrade or operationalize improvements to install or implement advanced industrial technology.

While fuels and clean energy are the main focus of the bill, bio-based chemicals impact our daily lives and have enormous potential to contribute to decarbonizing the US economy.

At DMC, we welcome this leadership to increase climate resiliency across communities in the US. As a company with advanced manufacturing technology which is both clean and economically-viable, we will be following closely to see how the program is rolled out.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “In addition to helping to decarbonize the chemicals industry, this support of advanced manufacturing companies will reduce our nation’s dependence on foreign suppliers and create new jobs in rural communities. This is a win-win-win for all Americans.”

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

For more information, visit: www.dmcbio.com

The post DMC Welcomes Inflation Reduction Act Inclusion of Advanced Manufacturing appeared first on DMC Biotechnologies.

Subsequent Close of Series B Financing, Total Raised $39 million

DMCBiotech — Mon, 31 Jan 2022 07:00:08 +0000

31 January 2022 – DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million.

DMC previously announced the first close of its Series B fundraising on 2 December 2021 with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “The addition of these strategic investors who have domain experience in nutrition and biobased chemicals, respectively, further enhances our opportunities to serve these market segments. We now have multiple strategic investors on board which validates our accomplishments to date and our potential. We are excited to continue growing the company to its next stage with the support of all of our stakeholders.”

DMC is commercial with its first product, a bio-based chemical intermediate with primary applications in sustainable detergents and human nutrition. DMC has a deep pipeline of predictable, scalable, and cost-competitive products that provide sustainable and economically attractive solutions for many industries, including animal nutrition, human nutrition, personal and home care, and biobased chemical intermediates.

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

About DMC
DMC is a US bio-based chemical company that makes products using microbial fermentation.
DMC’s proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable. For more information, visit: www.dmcbio.com

The post Subsequent Close of Series B Financing, Total Raised $39 million appeared first on DMC Biotechnologies.

DMC Announces First Close of Series B Financing, Raising $34 million

DMCBiotech — Thu, 02 Dec 2021 15:56:38 +0000

2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.

DMC is commercial with its first product, a bio-based chemical intermediate with primary applications in home care and human nutrition. The company has a deep pipeline of predictable, scalable, cost-competitive products, addressing sustainability challenges across a wide range of industries, including animal nutrition, human nutrition, personal and home care, and a broad range of chemical intermediates.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Building back better after the pandemic means we need to strengthen domestic manufacturing and improve supply chain resiliency. Biomanufacturing is one critical part of this strategy and DMC is positioned to be a significant part of this change. This financing will accelerate the commercialization of economically attractive and sustainable choices for consumers. We are excited to partner with our new investors and we are grateful for the continued support of our early investors as we advance DMC to the next stage.”

Alastair Cooper, Head of Venture Investments at Cibus said, “DMC has a truly unique technology platform which allows for the efficient production of bio-based chemicals applicable across a range of industries, most notably the human and animal nutrition markets. This substantially reduces the economic and environmental costs of production, allowing customers a more resilient and sustainable supply chain. We’re delighted to partner with Matt and his team who have demonstrated exceptional results at commercial scale already with far less time and cost than traditional biotech approaches.”

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

The post DMC Announces First Close of Series B Financing, Raising $34 million appeared first on DMC Biotechnologies.

DMC’s Downstream Processing Proven At Scale

DMCBiotech — Thu, 13 May 2021 08:51:17 +0000

13 May 2021 – DMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech in Leuna, Germany following the successful demonstration of commercial scale fermentation at the same site in March.

The purification of L-alanine from the fermentation broth was successfully completed for more than 6,000 kg of product. Product release testing has demonstrated that rigorous customer specifications for L-alanine were met.

Demonstration of the purification process and achievement of product specifications is the final proof point for DMC’s approach to producing L-alanine. As announced on 21 April 2021, L-alanine is now available at commercial scale following execution of a manufacturing agreement with Conagen.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “We recently announced the successful full commercial-scale demonstration of our fermentation process. Historically, fermentation scale-up has been a major stumbling block for early-stage companies. Delivering products to customers also requires successful purification and demonstration that the product meets the required specifications. We now have product with demonstrated quality metrics enabling customer adoption.”

Dr.-Ing. Markus Fritsch, Senior Project Manager at EW Biotech said, “It was a demanding project at a very unusual time. Preparations for the downstream processing (DSP) implementation in our facility went in parallel to the fermentation scale-up activities. With the deep contributions from our network of long-term partners we were able to deliver product that met target specifications. Thanks to DMC and our operating team at EW Biotech for making this project a joint success.”

EW Biotech Facility

About DMC

DMC is a US biobased chemical company that makes products using microbial fermentation. Their proprietary technology simplifies biology and makes fermentation more predictable, robust, and efficient. DMC is on track to address two of the global challenges of our time: sustainably and affordably feeding a growing world population and reducing greenhouse gas emissions through efficient production of (bio)chemicals.
For more information, visit: www.dmcbio.com

DMC media contact:

Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

About EW Biotech

EW Biotech is a leading service provider in the field of process development, scale-up, and custom manufacturing of biotechnological processes and products. For more information, see
www.ew-biotech.com or follow us on LinkedIn.
EW Biotech contact:

Isabel Waengler
Global Sales and Business Development
Isabel.waengler@ew-biotech.com

The post DMC’s Downstream Processing Proven At Scale appeared first on DMC Biotechnologies.

DMC & SCG Execute Agreement for DMC’s Amino Acid Product Line in ASEAN

DMCBiotech — Wed, 07 Apr 2021 11:49:24 +0000

7 April 2021 – DMC Biotechnologies has executed an agreement with SCG Chemicals Co., Ltd to bring DMC’s L-Alanine and branched chain amino acids (BCAAs) into the ASEAN* markets. SCG was an investor in DMC’s Series A round in December 2019.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “The SCG agreement is another validation of our technology and our progress towards the commercialization of our first wave of products. We are excited to partner with SCG and leverage their wide reach to distribute our products into the ASEAN region.”

Mr. Suracha Udomsak, CTO and Emerging Business Director, Chemicals Business at SCG said, “SCG is a leader in sustainable development and is working hard to respond to the global climate emergency. DMC has a new route to making more sustainable and affordable L-Alanine and branched chain amino acids. We are excited by the opportunity to bring these biobased, sustainable solutions to the region and to contribute to a more sustainable society.”

*Association of Southeast Asian Nations (ASEAN): Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam.

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

About DMC
DMC is a US biobased specialty chemical company which makes products using microbial fermentation. DMC’s metabolic engineering process simplifies biology to make fermentation more predictable, robust, and efficient. By unleashing the power of biology, DMC is on track to address two of the global challenges of our time: sustainably and affordably feeding a growing world population and reducing greenhouse gas emissions through efficient production of (bio)chemicals.
For more information, visit: www.dmcbio.com

About SCG
SCG is a conglomerate with headquarters in Bangkok, Thailand and operations throughout the South East Asian region. The company has three business units – Cement Building Materials, Packaging, and Chemicals. Packaging Business – SCG is a total packaging solutions provider and is integrated from the forest to the end product. Chemicals Business – SCG is a manufacturer of HVA polymers and functional materials.
For more information, visit: www.scg.com

The post DMC & SCG Execute Agreement for DMC’s Amino Acid Product Line in ASEAN appeared first on DMC Biotechnologies.

DMC Co-Founder Mike Lynch Publishes Technoeconomic Analysis (TEA) Calculator to Take the Guesswork Out of Bioprocess Development

DMCBiotech — Wed, 24 Mar 2021 11:29:55 +0000

24 March 2021 – DMC Co-Founder Mike Lynch has launched a web-based calculator to assess the economic feasibility of products made from fermentation. The Bioprocess Technoeconomic Analysis (TEA) tool will help users – academics, startups, funding agencies, R&D team, and investors – make commercially relevant decisions about technology development and deployment. The calculator connects key process and financial metrics to production costs and financial return.

Technoeconomic analysis (TEA) provides a quantitative method to assess the difference between something that is scientifically exciting and something that is economically attractive. By linking process parameters to financial metrics, all stakeholders can better understand the factors that will determine the success of their technologies. Historically, these types of analyses have been perceived as too complex, time-consuming, or expensive to be deployed in the earliest stages of R&D planning and evaluation. One of the objectives in publishing this tool is to remove those barriers so that every stakeholder – from researcher to investor – can make informed decisions about where they spend their resources.

TEA can be used in different ways. The R&D team can use this type of analysis to prioritize development efforts – focusing on the landscape of technical metrics that will have the greatest impact on their work. The Business Development team can use the tool to start with a market price and financial return that must be achieved and then rapidly identify projects that have the greatest probability of success.

One of the historical challenges in the field of industrial biotechnology is a lack of understanding of what is truly important from that which is scientifically exciting. This has resulted in substantial inefficiencies in the deployment of R&D capital, potentially affecting investor confidence in the sector as a whole. By demonstrating the capabilities of early-stage TEA in this new web-based tool, DMC hopes to encourage more stakeholders to prioritize this analysis from the very beginning of their development planning.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “The standards to have R&D work published in a peer-reviewed journal are very different than the requirements to create a viable business with commercial products. The development path from exciting basic science to commercial performance is often underestimated, if it’s understood at all. This calculator is a contribution to support the growth of the industrial biotech sector and is intended to provide the first steps in bridging the gap between science and commercial success.”

Screenshot of Bioprocess TEA Calculator

Links and media resources

– Bioprocess Technoeconomic Analysis tool http://www.bioprocesstem.com

– Video tutorials http://www.bioprocesstem.com/tutorials_main

– Michael D. Lynch, The bioprocess TEA calculator: An online technoeconomic analysis tool to evaluate the commercial competitiveness of potential bioprocesses, Metabolic Engineering, Volume 65, 2021, pp 42-51, https://doi.org/10.1016/j.ymben.2021.03.004

– Interview with CEO Matt Lipscomb ‘A successful biotech business is more than a science project’ https://youtu.be/Rs-_UxYiQ6U

About DMC

DMC is a US biobased specialty chemical company which makes products using microbial fermentation. DMC’s metabolic engineering process simplifies biology to make fermentation more predictable, robust, and efficient. By unleashing the power of biology, DMC is on track to address two of the global challenges of our time: sustainably and affordably feeding a growing world population and reducing greenhouse gas emissions through efficient production of (bio)chemicals.
For more information, visit: www.dmcbio.com

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

The post DMC Co-Founder Mike Lynch Publishes Technoeconomic Analysis (TEA) Calculator to Take the Guesswork Out of Bioprocess Development appeared first on DMC Biotechnologies.

DMC Demonstrates Full Commercial Scale at Record Speed

DMCBiotech — Thu, 18 Mar 2021 09:57:48 +0000

15 March 2021 – DMC Biotechnologies has successfully demonstrated full commercial scale (85m³ fermentation at EW Biotech, Germany) for its first product, the amino acid L-alanine.

The scale-up results identically tracked the performance at bench and pilot scales, further validating the predictability and scalability of DMC’s Dynamic Metabolic Control technology. Importantly, commercial performance metrics were demonstrated, meaning that no further strain improvements are required to achieve the target selling price.

This demonstration of process robustness and predictability across scale of production – from high-throughput screening to full commercial scale has never been demonstrated in the field and represents a major advancement for DMC. This core technology enablement will also be beneficial for DMC’s pipeline of products that will be scaled and commercialized next.

The scale-up process was conducted at EW Biotech’s facility in Leuna, Germany. According to Michael Katzberg, Managing Director at EW Biotech, “We are excited to report on the successful technology transfer and scale up of DMC’s process at the EW Biotech facility. This demonstration of process robustness and predictability of the strain across industrially relevant scale has the potential to radically improve the field of industrial biotechnology.”

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “A successful biotech business is about more than exciting science. Demonstration of performance at commercial scale with L-alanine validates the key technology features of robustness and predictability that will be inherent in all of our processes and demonstrates that we are on target with the economics for our lead product. We have reached commercial scale with unprecedented speed and capital efficiency when compared to any other company in the sector.”

EW Biotech GmbH Facility

About DMC

DMC is a US biobased chemical company that makes products using microbial fermentation. Their proprietary technology simplifies biology and makes fermentation more predictable, robust, and efficient. DMC is on track to address two of the global challenges of our time: sustainably and affordably feeding a growing world population and reducing greenhouse gas emissions through
efficient production of (bio)chemicals. For more information, visit: www.dmcbio.com

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com

About EW Biotech

EW Biotech contact:
Isabel Waengler
Global Sales and Business Development
Isabel.waengler@ew-biotech.com

The post DMC Demonstrates Full Commercial Scale at Record Speed appeared first on DMC Biotechnologies.

DMC Welcomes Rusty Pittman, VP of Business Development

DMCBiotech — Mon, 18 Jan 2021 19:02:50 +0000

18 January 2021 – Rusty Pittman joins the DMC team as VP Business Development. With over 25 years commercial experience in the chemical, building materials and renewable energy industries, Rusty joins DMC from Elevance Renewable Sciences, Inc where he spent the last six years as VP/Head of Marketing and Business Development.

Matt Lipscomb, Ph.D., CEO & Co-Founder of DMC said, “Rusty brings a wealth of expertise to DMC as we commercialize our first wave of products. He has a proven track record of successes across multiple industries and for a diversity of markets. We’re excited for him to join the team.”

“DMC has a robust technology platform, an impressive pipeline and a remarkable team and I’m excited to help them navigate new opportunities and accelerate the commercialization of various new products,” said Rusty Pittman. “They are well-positioned to make a significant impact in the chemicals industry and to positively contribute to the world’s need for sustainable and economical solutions.”

Photo of Rusty Pittman

About DMC

DMC media contact:
Kathryn Sheridan
Sustainability Consult
media@dmcbio.com
ks@sustainabilityconsult.com

The post DMC Welcomes Rusty Pittman, VP of Business Development appeared first on DMC Biotechnologies.